<DOC>
	<DOCNO>NCT00636246</DOCNO>
	<brief_summary>This study design determine novel combination SSRI , sertraline , NRI reboxetine increase antidepressant efficacy without sacrifice favorable safety profile SSRIs .</brief_summary>
	<brief_title>A Comparison Sertraline-Reboxetine Combination Therapy Versus Sertraline Reboxetine Monotherapy Treatment Major Depression .</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>Subjects must fulfill criterion MDD without psychotic feature define DSMIV , base clinical assessment confirm Structural Clinical Interview DSMIV Axis I DisorderClinical Version ( SCIDI ) plus MDD Specifiers include Research Version SCIDI . HAMD ( 17item ) ≥ 22 Screening ( Visit 1 ) &gt; 20 Baseline ( Visit 2 ) . Minimum CGIS ≥ 4 Screening ( Visit 1 ) Baseline ( Visit 2 ) . Known failure satisfactory respond adequate dose duration ( 12 week ) treatment clomipramine one SSRI , two SSRIs . Subjects &gt; 20 % HAMD ( 17item ) improvement ( decrease ) Screening ( Visit 1 ) Baseline ( Visit 2 ) . Subjects uncorrected hypothyroidism hyperthyroidism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>